Episode Details

This long-term clinical study evaluates the effectiveness of two different immunotherapy drugs in preventing the return of advanced melanoma following surgical removal. By tracking patients over a nine-year period, researchers demonstrated that nivolumab provides a more durable defense against cancer recurrence compared to ipilimumab. While both treatments showed similar results regarding total lifespan, patients receiving nivolumab experienced fewer distant metastases and required less follow-up systemic therapy. Ultimately, these final findings confirm that nivolumab remains a superior and safer standard for sustaining remission in high-risk skin cancer patients.